15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $22M | -$42M | 56.6% | -163.9% | -61.4% | -37.9% | -$26M | $31M | $22M |
| 2024 | $27M | -$43M | 49.1% | -213.6% | -59.4% | -36.0% | -$39M | $29M | $28M |
| 2023 | $20M | -$59M | 29.4% | -276.1% | -102.2% | -61.7% | -$31M | $29M | $37M |
| 2022 | $28M | -$62M | 34.9% | -205.4% | -77.7% | -52.2% | -$48M | $27M | $49M |
| 2021 | $21M | -$77M | 19.3% | -372.9% | -89.7% | -76.2% | -$51M | $0 | $36M |
| 2020 | $8M | -$29M | 33.2% | -394.7% | -104.6% | -83.2% | -$18M | — | $29M |
| 2019 | $8M | -$18M | 34.4% | -234.2% | -93.9% | -72.2% | -$16M | — | $20M |
| 2018 | $7M | -$18M | 23.9% | -239.2% | -199.5% | -126.4% | -$12M | — | $11M |
| 2017 | — | -$16M | — | — | -399.5% | -226.3% | -$11M | — | $4M |
| 2016 | — | -$11M | — | — | 166.4% | -281.2% | -$9M | — | $1M |
| 2015 | — | -$7M | — | — | 452.0% | -140.7% | — | — | $3M |
| 2014 | — | -$13M | — | — | 243.2% | -417.9% | — | — | $1M |
| 2014 | — | -$23M | — | — | 1817.2% | -401.4% | — | — | $4M |
| 2013 | — | -$14M | — | — | 16198.8% | -338.5% | — | — | $2M |
| 2013 | — | -$20M | — | — | 2390.6% | -301.3% | -$10M | — | $4M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $5M | -$8M | 61.7% | -125.1% | -14.4% | -8.2% | -$6M | $31M | $7M |
| Mar '26 | $6M | -$8M | 57.3% | -130.9% | -13.2% | -8.0% | -$6M | $31M | $15M |
| Dec '25 | $5M | -$9M | 53.6% | -163.7% | -13.3% | -8.2% | -$6M | $31M | $22M |
| Sep '25 | $5M | -$10M | 60.2% | -189.4% | -14.0% | -8.9% | -$7M | $31M | $32M |
| Jun '25 | $5M | -$13M | 55.2% | -171.4% | -20.3% | -12.0% | -$6M | $30M | $22M |
| Mar '25 | $7M | -$9M | 57.5% | -139.4% | -12.5% | -8.0% | -$7M | $29M | $28M |
| Dec '24 | $8M | -$10M | 55.3% | -153.4% | -13.4% | -8.1% | -$7M | $29M | $28M |
| Sep '24 | $7M | -$12M | 52.2% | -162.1% | -21.1% | -11.2% | -$7M | $29M | $16M |
| Jun '24 | $6M | -$14M | 44.1% | -258.8% | -20.0% | -11.1% | -$11M | $29M | $23M |
| Mar '24 | $6M | -$7M | 42.2% | -310.1% | -9.2% | -5.2% | -$13M | $28M | $34M |
| Dec '23 | $4M | -$14M | 3.7% | -393.1% | -24.6% | -14.8% | -$7M | $29M | $37M |
| Sep '23 | $4M | -$16M | 17.3% | -441.9% | -23.1% | -14.8% | -$9M | $29M | $44M |
| Jun '23 | $6M | -$17M | 33.7% | -227.9% | -21.2% | -14.2% | -$10M | $29M | $53M |
| Mar '23 | $7M | -$13M | 44.8% | -175.6% | -17.8% | -11.9% | -$5M | $17M | $39M |
| Dec '22 | $7M | -$13M | 40.1% | -132.3% | -15.8% | -10.6% | -$8M | $27M | $49M |
| Sep '22 | $7M | -$16M | 27.3% | -220.6% | -17.6% | -12.4% | -$11M | $24M | $57M |
| Jun '22 | $6M | -$18M | 18.4% | -280.7% | -18.1% | -13.1% | -$11M | $23M | $68M |
| Mar '22 | $8M | -$16M | 49.4% | -196.9% | -13.9% | -12.5% | -$18M | — | $56M |
| Dec '21 | $6M | -$22M | 9.1% | -359.4% | -25.2% | -21.4% | -$15M | $0 | $36M |
| Sep '21 | $6M | -$22M | 14.7% | -399.7% | -21.5% | -19.2% | -$13M | — | $51M |
How the market has priced DRIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, DarioHealth Corp.'s revenue has grown 24.2% per year. These are computed facts, not advice.
As of FY2025, DarioHealth Corp. reported $31M of total debt against $22M of cash; operating income covered interest expense -12.1×.
In FY2025, gross margin was 56.6%, operating margin -163.9%, and net margin -186.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.